M
Milan Basta
Researcher at National Institutes of Health
Publications - 27
Citations - 2164
Milan Basta is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Complement system & Antibody. The author has an hindex of 17, co-authored 27 publications receiving 1992 citations. Previous affiliations of Milan Basta include Johns Hopkins University & Walter Reed Army Institute of Research.
Papers
More filters
Journal ArticleDOI
Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke
Yang-Wei Fann,S-Y Lee,Silvia Manzanero,Sung-Chun Tang,Mathias Gelderblom,Prasad Chunduri,Christian Bernreuther,Markus Glatzel,Yi-Lin Cheng,John Thundyil,Alexander Widiapradja,Ker Zhing Lok,S L Foo,Y-C Wang Wang,Y-I Li,Grant R Drummond,Milan Basta,Tim Magnus,Dong-Gyu Jo,Mark P. Mattson,Christopher G. Sobey,Thiruma V. Arumugam,Thiruma V. Arumugam,Thiruma V. Arumugam +23 more
TL;DR: Evidence is provided that the NLRP1 and NLRP3 inflammasomes have a major role in neuronal cell death and behavioral deficits in stroke, and that IVIg treatment can protect brain cells against ischemic damage, suggesting a potential clinical benefit of therapeutic interventions that targetinflammasome assembly and activity.
Journal ArticleDOI
High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.
Milan Basta,Marinos C. Dalakas +1 more
TL;DR: It is concluded that IVIG exerts its beneficial clinical effect by intercepting the assembly and deposition of MAC on the endomysial capillaries through the formation of complexes between the infused immunoglobulins and C3b, thereby preventing the incorporation of activated C3 molecules into C5 convertase.
Journal ArticleDOI
F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins.
Milan Basta,Fredric Van Goor,Stefano Luccioli,Eric M. Billings,Alexander O. Vortmeyer,Lajos Baranyi,Janos Szebeni,Carl R. Alving,Michael C. Carroll,Ira Berkower,Stanko S. Stojilkovic,Dean D. Metcalfe +11 more
TL;DR: Molecular modeling, surface plasmon resonance (SPR) and western blot analyses suggested a physical association between anaphylatoxins and the constant region of F(ab)′2 that could interfere with the role of C3a and C5a in inflammation.
Journal ArticleDOI
Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death
Thiruma V. Arumugam,Sung-Chun Tang,Justin D. Lathia,Aiwu Cheng,Mohamed R. Mughal,Srinivasulu Chigurupati,Tim Magnus,Sic L. Chan,Dong-Gyu Jo,Xin Ouyang,David P. Fairlie,Daniel N. Granger,Alexander O. Vortmeyer,Milan Basta,Mark P. Mattson +14 more
TL;DR: A major role for complement-mediated cell death in ischemic brain injury is suggested and the prospect of using IVIG in relatively low doses as an interventional therapy for stroke is suggested.
Journal ArticleDOI
Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model.
TL;DR: It is suggested that supraphysiologic levels of IVIG act in part by preventing active C3 fragments from binding to target cells in response to complement-dependent tissue damage in a variety of diseases in man.